Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 14 Apr 2016 Status changed from not yet recruiting to recruiting.
- 01 Apr 2016 Trial design published in the Journal of Thoracic Oncology